One name in the biotechnology space that insiders have been loading up on shares of is Pharmacyclics (PCYC), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Insiders seem to have no problem paying up to own shares here since the stock is up over 70% so far in 2011. Whenever I see insiders buying a stock despite the fact that it has already advanced big, I take notice.
Pharmacyclics has a market cap of $629 million and an enterprise value of $561 million. This is a cash-rich company, with over $54 million in cash on their balance sheet and zero debt.The CEO just bought 678,000 shares, or about $6 millionworth of stock, at $8.85 per share. This same CEO also bought over $6 million worth of stock in PCYC back in June of 2010. The most recent purchase by this CEO was part of a private placement that helped raise over $57.1 million for the company. From a technical standpoint, this stock is very close to a major breakout if it can manage to take out $10.75 a share on the upside. A move above this level would mark a brand new 52-week high and would likely bring in some momentum traders. It's also worth noting that some huge upside volume has been flowing into this stock for the entire month of June. If you like this stock, I would trade the breakout if you see big volume flow into this name once it punches above $10.75. Look for volume that's well above the three-month average action of 572,000 shares. Use a mental stop that's a few percent below the breakout level just in case it fails to hold. This is a heavily shorted stock in which the bears are losing the battle. The current short interest as a percentage of the float is 9.1%. The short-sellers have also been increasing their bets from the last reporting period by 6.2%, or by about 233,000 shares. If PCYC breaks out soon, look for this high short interest to fuel the stock significantly higher. Pharmacyclics shows up on a recent list of 17 Breakout Stocks to Watch.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV